A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer

BACKGROUND: Our previous laboratory and clinical data suggested that one mechanism underlying the development of platinum resistance in ovarian cancer is the acquisition of DNA methylation. We therefore tested the hypothesis that the DNA hypomethylating agent 5-aza-2′-deoxycytodine (decitabine) can...

Descripción completa

Detalles Bibliográficos
Autores principales: Glasspool, R M, Brown, R, Gore, M E, Rustin, G J S, McNeish, I A, Wilson, R H, Pledge, S, Paul, J, Mackean, M, Hall, G D, Gabra, H, Halford, S E R, Walker, J, Appleton, K, Ullah, R, Kaye, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3992493/
https://www.ncbi.nlm.nih.gov/pubmed/24642620
http://dx.doi.org/10.1038/bjc.2014.116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3992493/
https://www.ncbi.nlm.nih.gov/pubmed/24642620
http://dx.doi.org/10.1038/bjc.2014.116

Ejemplares similares